# Leveraging Degrader Antibody Conjugates and Novel Ligases to Achieve Superior **Delivery, Efficacy and Selectivity**

Sean M. Peterson, Sumit Prakash, Anokha Ratnayake, Yiqian Li, Fei Ma, Andres Rojas, Daniel Medina-Cleghorn, Oscar Aguilera, Julie Sheung, Karim Mahiddine, Toni Hidalgo, Anna Kolobova, Alexandra Trotier, Mitchell Lavarias, Rolf Kern, Mark Noviski, Russell DeBarge, David Gygi, Emily Low, Stephanie Yung, Jeffrey Wu, Stefan Gajewski, Reza Karim, Brandon Bravo, Ratul Mukerji, Jamie Furneisen, Marie Malone, Paul Auger, Ryan Rountree, Christopher Phelps, Gwenn Hansen Nurix Therapeutics, Inc., San Francisco, CA





optimized DACs that are not currently predictable from their individual components.





NURIX